March 30, 2020
Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release
March 24, 2020
Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release
March 17, 2020
Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release
March 3, 2020
Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release
February 14, 2020
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release
February 14, 2020
Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release
13 février 2020
Biophytis shares trading is suspended pending a new press release. Read the Press Release
February 11, 2020
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release
JANUARY 27, 2020
Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release
JANUARY 10, 2020
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release